Abstract
The host kinase casein kinase 2 (CSNK2) has been proposed to be an antiviral target against β-coronaviral infection. To pharmacologically validate CSNK2 as a drug target in vivo, potent and selective CSNK2 inhibitors with good pharmacokinetic properties are required. Inhibitors based on the pyrazolo[1,5-a]pyrimidine scaffold possess outstanding potency and selectivity for CSNK2, but bioavailability and metabolic stability are often challenging. By strategically installing a fluorine atom on an electron-rich phenyl ring of a previously characterized inhibitor 1, we discovered compound 2 as a promising lead compound with improved in vivo metabolic stability. Compound 2 maintained excellent cellular potency against CSNK2, submicromolar antiviral potency, and favorable solubility, and was remarkably selective for CSNK2 when screened against 192 kinases across the human kinome. We additionally present a co-crystal structure to support its on-target binding mode. In vivo, compound 2 was orally bioavailable, and demonstrated modest and transient inhibition of CSNK2, although antiviral activity was not observed, possibly attributed to its lack of prolonged CSNK2 inhibition.
Funding Information
  • Bayer AG (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
  • Boehringer Ingelheim (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
  • Bristol Myers Squibb (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
  • Genentech (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
  • Genome Canada through Ontario Genomics Institute (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
  • EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
  • Janssen (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
  • Merck KGaA (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
  • Pfizer (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
  • Takeda (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
  • NC Biotech Center Institutional support grant (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
  • NIH Illuminating the Druggable Genome (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
  • Department of Defense ALSRP award (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
  • Rapidly Emerging Antiviral Drug Development Initiative (READDI) (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
  • Millennium Pharmaceuticals (Takeda) (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
  • National Institutes of Health (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)

This publication has 46 references indexed in Scilit: